Johnson & Johnson stock has returned 77.8% over the past five years and now sits at a point where a Discounted Cash Flow intrinsic value estimate suggests meaningful upside while broader valuation checks look much less generous. A DCF model using projected cash flows arrives at an estimated intrinsic value of about $390 per share, implying the stock screens roughly 34.0% undervalued versus the current price. However, the recent Illinois appellate ruling that upheld a $45 million mesothelioma verdict helps explain why the market may be more cautious. On an earnings basis, Johnson & Johnson trades at about 29.5 times earnings, slightly above its tailored fair P/E of 28.4 times and close to the peer average of 27.8 times, making it look roughly fairly valued on that metric. Overall, the DCF points to undervaluation while the earnings multiple suggests a full price, leaving the key question of whether legal and product uncertainties will fade enough for the market to treat the discount as an opportunity.
Johnson & JohnsonDCF suggests 34% undervaluation but earnings multiple shows fair value; legal uncertainty from talc verdict ruling clouds outlook.